Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$197,412 Mln
Revenue (TTM)
$36,741 Mln
Net Profit (TTM)
$7,711 Mln
ROE
1.1 %
ROCE
11.9 %
P/E Ratio
25.7
P/B Ratio
22.9
Industry P/E
--
EV/EBITDA
14.4
Div. Yield
2.6 %
Debt to Equity
6.3
Book Value
$15.9
EPS
$14.2
Face value
--
Shares outstanding
539,067,675
CFO
$97,559.00 Mln
EBITDA
$93,864.00 Mln
Net Profit
$64,460.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amgen (AMGN)
| 7.4 | -5.9 | 7.8 | 10.8 | 15.2 | 7.5 | 9.3 |
|
BSE Sensex*
| -12.4 | -11.4 | -12.2 | -1.5 | 8.6 | 8.6 | 11.5 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Amgen (AMGN)
| 25.6 | -9.4 | 9.7 | 16.7 | 0.9 | -2.0 | 27.6 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Amgen (AMGN)
|
351.5 | 1,97,412.0 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 25.7 | 22.9 |
| 208.3 | 3,88,431.4 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 92.7 | 50.5 | |
| 59.4 | 1,20,314.9 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 17.1 | 6.5 | |
| 918.1 | 8,81,665.1 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 42.9 | 32.9 | |
| 141.3 | 1,79,993.6 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 21.4 | 7.9 | |
| 237.3 | 5,82,038.9 | 94,193.0 | 26,804.0 | 34.6 | 35 | 21.9 | 7.2 | |
| 920.4 | 1,16,133.4 | 3,97,958.0 | 4,340.0 | 1.5 | -- | 27.2 | 5.0 | |
| 114.5 | 2,85,833.2 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 15.9 | 5.4 | |
| 149.8 | 2,96,610.3 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.5 | 6.3 | |
| 27.3 | 1,51,141.0 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 19.5 | 1.7 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of... adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he Read more
Chairman, CEO & President
Mr. Robert A. Bradway
Chairman, CEO & President
Mr. Robert A. Bradway
Headquarters
Thousand Oaks, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Amgen Inc (AMGN) is $351.48 (NASDAQ) as of 18-Mar-2026 16:22 EDT. Amgen Inc (AMGN) has given a return of 15.22% in the last 3 years.
The P/E ratio of Amgen Inc (AMGN) is 25.70 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
23.05
|
20.53
|
|
2024
|
34.54
|
24.04
|
|
2023
|
23.15
|
24.96
|
|
2022
|
21.61
|
38.67
|
|
2021
|
21.57
|
18.97
|
The 52-week high and low of Amgen Inc (AMGN) are Rs 391.29 and Rs 261.43 as of 19-Mar-2026.
Amgen Inc (AMGN) has a market capitalisation of $ 197,412 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Amgen Inc (AMGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-9.65
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.